未找到相关数据
Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
被引：15
作者：
Verma, S.
DeMichele, A. M.
Loi, S.
Ro, J.
Colleoni, M.
Iwata, H.
Harbeck, N.
Stearns, V.
Cristofanilli, M.
Bartlett, C. Huang
Schnell, P.
Zhang, K.
Thiele, A.
Turner, N. C.
Rugo, H. S.
机构：
[1] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
[4] Univ Melbourne, Parkville, Vic 3052, Australia
[5] Natl Canc Ctr, Goyang Si, Gyeonggi Do, South Korea
[6] Ist Europeo Oncol, Milan, Italy
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[8] Univ Munich, Brustzentrum, Munich, Germany
[9] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[11] Pfizer Inc, New York, NY USA
[12] Pfizer Inc, San Diego, CA USA
[13] Pfizer Inc, Cambridge, MA USA
[14] Royal Marsden Hosp, London SW3 6JJ, England
[15] UCSF Med Ctr Mt Zion, San Francisco, CA USA
来源：
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-13-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-13-03
引用
收藏
页数：2
相关论文